ADMA BIOLOGICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on December 23, 2015, reporting an event that occurred on December 18, 2015. The Company is a Delaware corporation focused on the development and commercialization of plasma-derived therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material definitive agreement and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the execution of Amendment No. 2 to the Plasma Purchase Agreement with Biotest Pharmaceuticals Corporation, originally dated November 17, 2011. This amendment modifies the terms regarding the purchase of normal source plasma containing antibodies to Respiratory Syncytial Virus (RSV) for the manufacture of the Company's product, RI-002.
Outlook, Risks, and Management Commentary
Amendment No. 2 expands the circumstances under which the Company may purchase additional plasma from sources other than Biotest. This change provides the Company with greater flexibility in its supply chain for RSV-containing plasma. The filing does not include specific forward-looking guidance, risk factors, or unusual items beyond the details of this agreement.
Key Facts for Investor Verification
- Verify the specific conditions and limitations under which ADMA Biologics may now source plasma from suppliers other than Biotest.
- Confirm the impact of this amendment on the production capacity and supply security for RI-002.
- Review the original Plasma Purchase Agreement to understand the baseline restrictions that were modified.